ORIGINAL RESEARCH PAPER INTERNATIONAL JOURNAL OF PURE MEDICAL RESEARCH

Oncology

KEYWORDS: Radiotherapy, brachytherapy, pancreatic cancer therapy

RADIOTHERAPY IS ONE OF THE EFFECTIVE AND COMMON MEASURES OF PANCREATIC CANCER THERAPY: IODINE-125 (125I) BRACHYTHERAPY IMPROVES LOCAL CONTROL AND INCREASE SURVIVAL

Volume-2, Issue-11, November - 2017

Hafiza Sobia Ramzan* Institute of molecular biology and biotechnology, University of the Lahore, Lahore*Corresponding Author biochemist_uol@yahoo.com

Mariam Awan Institute of molecular biology and biotechnology, University of the Lahore, Lahore

Dr. Hafiz Faizan Lateef Nawaz Shareef Medical College, Gujrat.

Dr Qamar Zaman Medical Officer at Basic Health Unit 39/DNB

Article History
Received: 03.08.2017
Accepted: 16.10.2017
Published: 10.11.2017

ABSTRACT:

Introduction: The malignant tumors of torment and life taking pancreatic cancer account for adeno-carcinoma which finds its origin in the exocrine secretions of pancreas. Though a lot many techniques and methodologies are surfacing in the field of medical science but still the overall survival rate is not remarkable. The recommended treatment for local tumor control is the implantation of the I125 radioactive seed (brachytherapy) in the effected organ. Objective: This study was carried out in order to reveal the individual and synergistic efficacy of I125 and ING4 for the treatment of pancreatic cancer tumors. Both in vitro (pancreatic cell lines) and in vivo (in mouse model) investigations were performed.

Material and methods: The vibrant combination of ING4 and radiotherapy with I125 for treating pancreatic cancer had been done before this appraisal unknown. We investigated that whether ING4 and I125 radiotherapy treatment can suppress Panc-1 pancreatic cancer cell tumor growth or not using in vitro and in vivo substrates.

Results: In this study, we demonstrated that either ING4 or (125)I radiotherapy treatment could induce Panc-1 pancreatic cancer cell growth suppression and apoptosis in vitro. The outcomes revealed that both treatments inhibited can inhibit the malignancy of pancreatic cancer with their tumor suppressive functions. Hence (ING4) gene therapy plus (I125) radiotherapy had produced synergistic effects.

Introduction

The malignancy of pancreatic tissues is chronic and even becomes acute in severe cases. This very rapidly growing carcinoma aggressively spread in pancreas of human body and may sometimes take entry into nearby organs in shape of secondary cancer if not properly treatedon time.. If we look in the recent history of human death rate the devastations of pancreatic cancer are significant.Early prognosis can reduce the devastating effects of pancreatic cancer. Although medical science has devised various therapeutic treatment options and techniques for pancreatic cancer but unfortunately the outcomes are disappointing. Even the combined treatments of external beam radiotherapy (EBRT) and chemotherapy have shown unsatisfactory results for the prognosis of pancreas malignancy. 90% alarming mortality rate has been reported by this menace (Geer & Brennan, 1993)

It is worthwhile to mention here that the cancerous pancreas is rarely transformed to healthy organ with the deployment of conventional surgical and chemotherapeutic treatments. Similarly nearly 20% patients get long and eventual cure (Levin et al. 1978; Crile, 1970). The need of time is to introduce new innovative therapeutic techniques for the rest of the lot suffering from the same painful ailment (Joyce et al. 1990). Gastric bypass has somehow palliative effects upon malignant pancreas as it increases chances of survival for the patient upto half a year (Schwarz and Beger, 2000; Khan et al. 2010).

Since radiotherapy is commonly usedmethod for curing cancer disease along with surgical treatment and chemotherapy For the purpose of subjecting only cancerous organ with great precision the targeted dose of radiations are conformed as blocking techniques for tumor. Computerized imaging has helped a lot in shielding the local healthy organs from high dose and effects of radioactive beam. (Foote et al. 2012). However the transformations in the shape or size during treatment phase can be governed precisely by the means of adequate, appropriate and advanced radiation therapy techniques. This is because the radiotherapy delivers the required dose for the malignant tissues leaving very little exposure to the nearby healthy tissues (Van der Meer and Stehouwer, 2005). With the advancement radiology these radiations are either given outside in (EBRT) or inside out (Brachytherapy).Treating cancer tumor from inside is effective for only delivering radiation to the targeted mass of the affected organ (De Vries, 2009).

Radiotherapy increases the probability of controlling the tumor size and its threats. Four-dimensional imaging assists the radiologist to restrain radiations only within the affected cancerous organ. Similarly, the effectiveness of radiotherapy is relevant to the dose of exposure given to the organ and response that is being shown by that very specifically subjected organ (Bentzen et al. 2010). In this regard various advancements in the radiotherapy technique are evident for increasing the survival rate of patients suffering from pancreatic cancer. Sometimes the conglomeration of radiotherapy, chemotherapy and biologically targeting are used to enhance OS (overall survival rate) of the cancer affected individuals (Foote et al. 2012). But all the techniques go in vain if the tumor recurs (Shi et al. 2012). In response to such difficulty and challenging situations there is an imperative need to provide optimumdose of radiation for targeting the unhealthy organ in order to avoid the recurrence of cancer (Foote et al. 2012).

For the improvement after the prognosis of cancer various adjuvant treatments are used in combination with radiotherapy in order to inhibit recurrence (Lai et al. 1998; Takenaka et al. 1995). Debates are still surfacing in field of medical science for the effectiveness of

irradiation therapies given to the subject externally for pancreatic carcinoma(Mattiucci et al. Furuse et al. 2010; Kouloulias et al. 2002).

The research conducted by Minsky et al. 1988 revealed the fact that External beam radiotherapy therapy (EBRT) plus chemotherapy are extensively suggested by the radiologists to the pancreatic cancer patient. In combination of these two therapies sometimes intraoperative electron beam radiotherapy is also used but unsatisfactory outcomes are found (Blasko et al. 2002; Wang et al. 2010; Cengiz et al. 2008; Monk et al. 2002). Though this combination relieves pain to the significant level but has severe effects on patient's body and increase only median survival rates.The OS (overall survival rate) is very less in case of using Also EBRT alone (Bodner et al. 2000; Nag et al. 2006)

The victims with loco-regional recurrence of cancer may be treated with conventional cancer treatments or with EBRT (Makela et al. 1985; Nunobe et al. 2010) but as an alternative and effective treatment for rapidly growing pancreatic cancer the Brachytherapy with Iodine-125 is widely used nowadays. This therapy has minimal side effects for the healthy volume of the organ (Wang et al. 2011).

Basically brachytherapy is permanent implantation of radioactive seeds are useful for controlling localized tumors of pancreatic carcinoma in the treatment of pancreatic cancer (Mohiuddin et al. 1992; Takacsi et al. 2002; Sun et al. 2005; Enomoto et al. 2006). Radioactive iodine-125 seed implantation has shown good results for treating resectable pancreatic carcinoma (Ebara et al. 2008; Siegel et al. 1988; Holm et al. 1981).The interesting thing about brachytherapy is that the dose for the targeted volume of the cancerous tissues can be increased by placing radioactive seed inside the targeted organ and then subjecting it with the emission of stable and quick gamma rays. During this localized and targeted radiation the dose of radiation is of low energy (e.g iodine-125 seed) hence minimizing the impacts on surrounding tissues.

Since brachytherapy is targeted so its remains unaffected by the boy posture, motion, respiration and other interferences. Not only pancreatic cancer is treated with this therapy but other chronic cancers like head, neck and pulmonary carcinoma etc. are also cured (Haung et al. 2009; Hoqwitz et al. 1997; Goertz et al. 1990; Son and Ariyan 1985; Zhang et al. 2007).

Iodine-125, iridium-192 or palladium-103 seeds are mostly used in brachytherapy to be implanted inside the malignant tissue. But out of these commonly used seeds iodine-125 seed is the most recommended one because half-life of this radioactive element reaches upto 59.7 days,. In contrast to high energy radioactive seed like radium-226 the low-energy iodine-125 seeds are successively used form the last 30 years (Wuu et al. 1996)Hence significantly reduces chance of tumor recurrence and controlling growth of pancreatic carcinoma (Du et al. 2011). Moreover brachytherapy with Iodine-125 seed treatment is an effective remedy for getting marked response from malignant tumor and it is being used from many years (Aronowitz, 2002). Brachytherapy combined with other adjuvant therapy for treating cancer did not show successful results (Jin et al, 2008).

Material and methods

The Quick Change Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) was used to generate mutant versions of ING4; with the help of the complementary DNA of the human ING4 protein, which used the retroviral vector pLPC(variant v1;24) as a template for cloning purpose. PCR via Pfu Turbo DNA polymerase (strata gene) was used to incorporate specific mutations. DpnI was subsequently used to splice the methylated parental band. These fragments thus formed, were verified with the help of gene sequencing. Overall all Panc-1 cells were divided in three main groups in their log growth phase;

1. Two experimental groups (AdING4, AdING4 plus I125group)

2. Negative control group Ad-Green Fluorescent Protein or AdGFP group

3. Two cell control group I125 and PBS group

In Vitro Investigation

In vitro study was conducted by keeping the temperature at 37°C, during plate culture for each group. All cultured plates were observed under high resolution fluorescent microscope and with DIC (differential interference contrast).

In Vivo Investigation

Similarly, for in vivo investigations, 10 nude mice (divided in five groups i.e. two mice per group) were taken and injected with the aforementioned solutions. The tumor growth for both studies (in vivo and in vitro) was recorded and observations thus made were as follows:

Results

Morphological investigations in Panc-1 infected cells

Panc-1were introduced to doses of 100 MOI of AdING4, I125and AdGFP (109pfu/mL) for 72 hours. Upon investigation of morphological changes in these infected cells (via fluorescent light microscope), it was observed that under the conditions of AdGFP and PBS solutions, the cells retained their structure and growth quite well. Whereas, those introduced to AdING4 cultures exhibited significant abnormalities in both structure and adherence (which were reduced significantly). In addition the cells introduced to AdING4 and AdGFP showed remarkable green fluorescence.

Inhabitance of Growth

The significant inhibition in growth rate was observed in Panc-1 cells in the culture plates containing AdING4. The rate of inhibition was about 50-60% within 4 to 5 days of observation (<0.05). The results showed that AdING4 gene can inhibit the growing Panc-1 cells.

Presence of Apoptosis

Those Panc-1 cells which were subjected to I125, AdING4 plus I125 AdING4 after staining showed the clear indications for apoptosis (condensation and beak down of nucleus). However, the percentage of apoptotic cells was significantly higher in the I 125 as compared to AdING4 $p > 0.05$. Data shown are representative of three independent experiments. In the remaining groups no apoptosis was detected at all.

mRNA transcripts

The Panc-1 cells having 100 MOI AdGFP and AdING4 infection were used to extract the RNA followed by RTPCR in order to read the mRNA transcriptions. There sequence of Bcl2, Bax, p53, Fas, Survivin and Caspase3 were focused. Significantly Bcl2's down regulation was recorded for the cells containing ING4.Along with it the upregulation of Bax, Caspase3 and p53 genes was observed for the same cultures.

Growth rate of Tumors

The growth of tumor was observed in all 10 mice belonging to each group. But tumors were limited to the subcutaneous layer. Thereafter the growth was successively increased. Significant slow growth of tumors was achieved in the mice inoculated with I125, ING4 and ING4. In PBS and AdGFP groups the rate of tumor growth was much higher and continuous.

The tumor growth in experimental groups i.e.I125, I125 plus AdING4 and AdING4 was very small compared to the rest of the groups (<0.05). No remarkable change in volumes if tumor was noticed between the controlled and negative control groups (PBS and AdGFP respectively).

Tumor Cell Physiology

For the clear view some specimens of the tumors were perfectly stained with HE. The expected outcomes were observed. The

tumors in I125, ING4 and I125 plus ING4 were having necrosis with the shrinkage, non-cellular appearance and pink fragmentations of cells. Whereas, the tumors in PBS and AdGFP groups had pathologic division of cells.

No significant change in the expression of genes was recorded for controlled and negative controlled groups.

Discussion

The discovery of ING1 brought the innovation in the world of genetics, opened the doors for the detection of other ING members and isoforms of inhibitors of growth (ING2-5) which were associated with cell cycle, apoptosis and senescence (Gunduzet al, 2008). They also consist of the tumor suppressor genes TSG (ING1, ING2, ING3, ING4 and ING5) the suppression involves such mechanisms which includes the interactions with the chromatin function and gene specific transcription, these also controls the cell cycles, DNA repair and apoptosis.

Apoptosis is induced by ING4 on the tumor cell virtue with an increased p53 transcription which consequently shortens the S phase of cancer cells and enhances the G2/M phase simultaneously arrest of HepG2 liver cancer cells. Nuclear localization signals and N-terminal sequences are present in the inhibitors of the growth which plays an important role in interacting with histone acetyl transferase (HAT) and histone de-acetyl transferase (HDAC) that helps in regulating the activity in the gene promotion within chromatin (Kishimoto et al, 2006). ING4 induces tumor cell apoptosis by virtue of an increased p53 transcription which subsequently results in shortening the S phase of RKO colon cancer cells and simultaneously enhancing the G2/M phase arrest of HepG2 liver cancer cells.

Previous studies suggest that the class of ING is capable to regulate those chemical agents that can damage or even destroy the DNA hence it can inhibit the transmission of mutant gene in neighboring cells. ING4 curbs the movement of tumor cell by interaction with liprin α 1 protein. All such actions and activities depict the antitumor effects including various mechanisms and pathways.



ING4 recombinant adenovirus vector alone did not show any response on gene therapy for pancreatic cells. Therefore Panc-1 was introduced in the infected cells in vitro with adenovirus for investigation of the individualeffects of AdING4 and the associated growth mechanismidentification. The gene was successfully transfected into Panc-1 cells by ING4 proved by RTPCR.

The adenovirus induced ING4 gene expression drastically inhibits the proliferation of Panc-1 cell which enhances apoptosis with 20 % rate. That is higher than the (PBS) cell control group. The cells staining and observation was done using Hoechest 33258 laser scanning confocal microscopy. These further supported that AdING4 plus I125 induced cell apoptosis and nuclear morphological changes in Panc-1 cells, whereas no apoptotic nuclear morphological changes in AdGFP and PBS groups were seen. Investigation using RTPCT of the molecular mechanisms of the antitumor effects of ING4 genes was also conducted. After transfection of ING4, the gene promoting apoptosis Bax transcription was up regulatedand in the mean while down regulation of anti apoptosis gene Bcl2 was recorded. Thereafter the ratio Bax:Bc12 becomes higher. Moreover, the increase in the transcription of the tumor suppressor gene p53 that aids in activation of the Caspase3 causes cleavage of Caspase3. This cleavage is the clear evidence of apoptosis which has been induced to the cancer cell the cleave indicates the enhanced ING4 p53 transcription, and apoptosis of induced tumor cell by a pathway dependant on p53.

The tumor treatment was also experimented in the nude mice with AdING4 and I125. This combination inhibits the growth rate completely. These results of experiments signals out that ING4 can inhibit the growth of the transplanted tumor specifically. Massive necrosis regions were seen in the mice after the use of AdING4, I125, AdING4 plus I125 whereas negative control groups still consisted the tumor cells having mostly cells in the mitotic phase. The numerical scale of apoptotis of AdING4 group was importantly higher than in the AdGFP and PBS control groups.

The upregulation of Bax gene in the antitumor effect of AdING4 and down regulation of Bcl2 gene activates the Caspase3 pathway results in the apoptosis. A Vitro study also produces the consistent behavior. This study proves the experimental evidence which supports the possibilities of the gene therapy for the treatment of pancreatic cancer with the combination of I125 plus AdING4. This combination increases the survival rate of the people having pancreatic ailment. Therefore, as compared to the individual effects of ING4 and I125their synergistic effects for the tumor growth inhibition are much more useful to reduce the mortality rate of pancreatic cancer.



Fig. 1: Adenovirus-mediated ING4 expression. Panc-1 cells were treated with PBS, Ad-GFP, Ad-hING4, 125I, and Ad-hING4 plus 125I and were observed with fluorescence and differential interference contrast (DIC) microscopy



Fig. 2: Inhibition assay of tumor growth in vivo. The morphological observations of tumor tissues in different groups.



Figure 3: Detection of apoptosis-related molecules in Panc-1 human pancreatic carcinoma s.c.xenografted tumors cells by immunostaining. Representative immune histochemical pictures of Caspase-3, Fas, Bax, Bcl-2 and Survivin in Panc-1 pancreatic

carcinoma xenografted tumors .



Figure 4: The percentagof apoptotic cells was significantly higher in the 125I as compared to hING4 p > 0.05 when the Ad group was compared with the PBS group).Data shown are representative of three independent experiments



Figure 5: Colony formation assay. Compared with group hING4 with 125I groups.I125 is higher were significantly higher

REFERENCES

1. Aronowitz J.N., 2002. Buried emanation; the development of seeds for permanent implantation. Brachytherapy 1: 167–178.
2. Bentzen S.M., L.S. Constine, J.O. Deasy, A. Eisbruch, A. Jackson, L.B. Marks et al. 2010. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J RadiatOncolBiolPhys 2010, 76(3 Suppl):S3–S9.
3. Blasko J.C., T. Mate, J.E. Sylvester, P.D. Grimm, W. Cavanagh .2002. Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes. Seminar Radiation Oncology , Vol. 12, No. 1.
4. Bodner W.R., B.S. Hilaris and D.A. Mastoras . 2000. Radiation therapy in pancreatic cancer: current practice and future trends. Journal of Clinical Gastroenterol.Vol. 30, No. 3.
5. Cengiz M., S. Gurdalli, U. Selek, F. Yildiz, Y. Saglam, E. Ozyar and I.L. Atahan. 2008. Effect of bladder distension on dose distribution of intracavitary brachytherapy for cervical cancer: three-dimensional computed tomography plan evaluation. International Journal of Radiation Oncology and Biological Physiology, Vol. 70, No. 2.
6. Connell P.P. and S. Hellman. Advances in radiotherapy and implications for the next century: a historical perspective. Cancer Res 2009;69(2):383–92.
7. Crile G.Jr., The advantages of bypass operations over radical pancreatoduodenectomy in the treatment of pancreatic carcinoma.SurgGynecolObstet,Vol. 130, No. 6.
8. De Vries, J., W. van der Graaf, H. Hollema, E. Haagedoorn and B. Szabó. 2009. Oncologievoor de algemenepraktijk (2de ed.). Assen: Van Gorcum.
9. Ebara S., N. Katayama, R. Tanimoto, K. Edamura, H. Nose, D. Manabe, T. Kobayashi, Y. Kobayashi, M. Kobuk, M. Takemoto, T. Saika, Y. Nasu, S. Kanazawa and H. Kumon. 2008. Iodine-125 seed implantation (permanent brachytherapy) for clinically localized prostate cancer. Acta Med Okayama, Vol. 62, No. 1: 9–13
10. Enomoto T., T. Oda, Y. Aoyagi, S. Sugiura, M. Nakajima, M. Satake, M. Noguchi and N. Ohkohchi. 2006. Consistent liver metastases in a rat model by portal injection of microencapsulated cancer cells. Cancer Res, Vol. 66, No. 23
11. Foote R., S.L Stafford, I.A Petersen, J.S Pulido, M.J Clarke, S.E Schild, Y.I Garces, K.R Olivier, R.C Miller et al.2012. Clinical case for proton beam therapy.International journal of Radiation Oncology. Vol. 7:174.
12. Furuse J., T. Kinoshita, M. Kawashima, H. Ishii, M. Nagase, M, Konishi, T. Nakagohri, K. Inoue, T. Ogino, H. Ikeda, Y. Maru and M. Yoshino. 2003. Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma. Cancer, Vol. 97, No.5.
13. Geer R.J. and M.F Brennan. 1993. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg, Vol. 165, No. 68–72
14. Goertz S.R., M.M. Ali, G.A. Parker. 1990. Local management of pancreatic carcinoma: iodine-125 implantation. Clinical Oncology (R CollRadiol) 2: 22–26.
15. Grimm P., and J. Sylvester. 2004. Advances in brachytherapy. Rev Urol 2004;6 Suppl 4:S37–48
16. Gunduz M., E. Gunduz, R.S. Rivera, Nagatsuka H. 2008. The inhibitor of growth (ING) gene family: potential role in cancer therapy. Current Cancer Drug targets, 8(4):275-84.
17. Gupta V.K. 1995.Brachytherapy - past, present and future.J Medical Physics. Vol. 20 (2):31–5.
18. Holm H.H., H. Stroye, H. Hansen and F. Stadil.1981.Ultrasonically guided percutaneous interstitial implantation of iodine 125 seeds in cancer therapy.Br J Radiol, Vol. 54, No. 644-70.
19. Horwitz E.M., A.J. Frazier, F.A. Vicini, D.H. Clarke, G.K. Edmundson et al. 1997. The impact of temporary iodine-125 interstitial implant boost in the primary management of squamous cell carcinoma of the oropharynx. Head Neck 19: 219–226.
20. Hoskin P.J. and P. Bownes.Innovative technologies in radiation therapy.2006.Brachytherapy. Seminar Radiation Oncology;16(4):209–17.
21. Huang K., P.K. Sneed, S. Kunwar, A. Kragten, D.A.Larson. et al. 2009. Surgical resection and permanent iodine-125 brachytherapy for brain metastases.Journal Neuro oncology 91: 83–93.
22. Jin Z., Y. Du, Z. Li, Y. Jiang, J. Chen, Y. Liu. 2008. EUS-guided interstitial implantation of iodine 125 seeds combined with chemotherapy in the treatment of unresectable pancreatic carcinoma: a prospective pilot study. Endoscopy, 40:314-20.
23. Joyce F., F. Burcharth, H.H. Holm and I. Stroyer.1990.Ultrasonically guided percutaneous implantation of iodine-125 seeds in pancreatic carcinoma.International Journal of Radiation Oncology BioogylPhysiology, Vol. 19, No. 4: 1049-1052
24. Khan I.M., M. Aurangzeb.Mujeeb-Ur-Rahman and M. Tayyab. 2010. Palliative surgery for pancreatic carcinoma. Journal of Coll Physicians Surg Pak, Vol. 20, No. 11:719-722
25. Kim M.S., S.Y. Yoo, C.K. Cho, H.J. Yoo, K.M. Yang, J.K. Kang, D.H. Lee, J.I. Lee and H.Y. Bang.2009. Stereotactic body radiotherapy for isolated para-aortic lymph node recurrence after curative resection in gastric cancer.Journal of Korean Medical Science. Vol. 24(3):488–492.
26. Kishimoto M.A, R .Y. Fujiki, S. H. Takezawa, Y.A. Sasaki, T. Nakamura, K. A Yamaoka, H.I. Kitagawa and S.H. Kato. A Review, Nuclear Receptor Mediated Gene Regulation through Chromatin Remodeling and Histone Modifications Endocrine Journal 2006, 53 (2), 157–172.
27. Koulouilas V.E., J.R. Kouvaris, K.S. Nikita, B.C. Golematis, N.K. Uzunoglu, K. Mystakidou, C. Papavasiliou and L. Vlahos.2002.Intraoperative hyperthermia in conjunction with multi schedule chemotherapy (pre-, intra- and post-operative), by-pass surgery, and post-operative radiotherapy for the management of unresectable pancreatic adenocarcinoma. International Journal of Hyperthermia, Vol. 18, No. 3.
28. Lai E.C., C.M. Lo, S.T. Fan, C.L. Liu, J. Wong. 1998. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 133: 183–188.
29. Levin B.,W. H. ReMine, R.E. Hermann, P.S. Schein, I. Cohn.1978. Panel: Cancer of the pancreas. Am J Surg, Vol. 135, No. 2:185- 191.
30. Liangrong S.,W. Changping, W. Jun, W. Zhou, M. Ji, H. Zhang, J. Zhao, Y. Huang, H. Pei, Z. Li, J. Ju and J. Jiang. 2012. Computed tomography-guided permanent brachytherapy for locoregional recurrent gastric cancer. Radiation Oncology. Vol.7:114.
31. Makela J., and M.I. Kairaluoma.1985.Rationale of reoperation for gastric malignancies. Ann ChirGynaecol. Vol. 74(2):77–81.
32. Mattiucci G.C., A.G. Morganti, V. Valentini, E. Ippolito, S. Alfieri, A. Antinori, A. Crucitti, D'Agostino G.R., L. Di Lullo, S. Luzi, G. Mantini, D. Smaniotto, G.B. Doglietto and N. Cellini.2010.External beam radiotherapy plus 24-hour continuous infusion of gemcitabine in unresectable pancreatic carcinoma: long-term results of a phase II study. . International Journal of Radiation Oncology and Biological Physiology.Vol. 76, No. 3.
33. Minsky B.D., B. Hilaris and Z. Fuks. 1988. The role of radiation therapy in the control of pain from pancreatic carcinoma. J Pain Symptom Manage, Vol. 3, No. 4.
34. Mohiuddin M., F. Rosato, D. Barbot, A. Schuricht, W. Biermann and R. Cantor. 1992. Long-term results of combined modality treatment with I-125 implantation for carcinoma of the pancreas. Int J RadiatOncolBiolPhys, Vol.23, No.2.
35. Monk B.J., K.S. Tewari, K.S, A.A. Puthawala, A.A, A.M. Syed, J.A. Haugen and R.A. Burger.2002.Treatment of recurrent gynecologic malignancies with iodine-125 permanent interstitial irradiation. . International Journal of Radiation Oncology and Biological Physiology.Vol.52, No. 3.
36. Nag S., M. Dehaan, G. Scruggs, N. Mayr and E.W. Martin.2006. Long-term follow-up of patients of intrahepatic malignancies treated with iodine-125 brachytherapy. International Journal of Radiation Oncology Biological Physiology, Vol. 64, No. 3.
37. Nunobe S., N. Hiki N, S. Ohyama, S. Aikou, T. Sano, T. Yamaguchi. 2010. Outcome of surgical treatment for patients with locoregional recurrence of gastric cancer. Langenbeck's Arch SurgDeutGesChir. Vol. 396(2):161–166.
38. Schwarz A., and H.G. Beger. 2000. Biliary and gastric bypass or stenting in nonresectableperiampullary cancer: analysis on the basis of controlled trials. International Journal of Pancreatology, Vol.27, No. 1:51-58.
39. Siegel J.H., J.L. Lichtenstein, W.E. Pullano, W.H. Ramsey, A. Rosenbaum, G. Hhlpern, R. Nonkin and H. Jacob. 1988. Treatment of malignant biliary obstruction by endoscopic implantation of iridium 192 using a new double lumen endoprosthesis. GastrointestEndosc, Vol. 34, No. 4:301-306
40. Son Y,H. and S. Ariyan. 1985. Intraoperative adjuvant radiotherapy for advanced cancers of the head and neck. Preliminary report. Am J Surg 150: 480–484.
41. Sun S.L., Qingjie, G. Qiyong, W. Mengchun, Q. Bo and X. Hong. 2005. EUS-guided interstitial brachytherapy of the Pancreas: a feasibility study. GastrointestEndosc, Vol. 62, No. 5.
42. Takácsi N. Z., J. Varga, I. Poller, J. Fodor, C. Polgár, A. Petrányi, T. Major, and G. Németh. 2002. Successful treatment of a T1 cancer of the pancreatic head with high dose rate brachytherapy and external radiotherapy. Hepato-gastroenterology, Vol. 49, No. 45
43. Takenaka K., K. Yoshida, T. Nishizaki, K. Korenaga, K. Hiroshige. 1995.Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma. AmJSurg 169: 400–404, 405.
44. Van der Meer., J and C. Stehouwer. 2005. Interne geneeskunde (13de ed.). Houten: Bohn Staeu van Loghum. voor de algemenepraktijk (2de ed.). Assen: Van Gorcum.
45. Wang Z., J. Lu, L. Liu, T. Liu, K. Chen, F. Liu, G. Huang. 2011. Clinical application of CT-guided (125)I seed interstitial implantation for local recurrent rectal carcinoma. Radiation Oncology Vol. 6:138.
46. Wang Z.M., Y. Liu, F.J. Liu, K.M. Chen and G Huang.2010.Clinical efficacy of CT-guided iodine-125 seed implantation therapy in patients with advanced pancreatic cancer. EurRadiol, Vol. 20, No. 7.
47. Wuu C.S., P. Kliauga, M. Zaider, H.I. Amols.1996. Microdosimetric evaluation of relative biological effectiveness for 103Pd, 125I, 241Am, and 192Ir brachytherapy sources. International Journal of Radiation Oncology Biology Physiology 36: 689–697.
48. Zhang F.J., C.X. Li, P.H. Wu, Y.X. Wu, D.C. Jiao, et al. 2007. CT guided radioactive 125I seed implantation in treating localized advanced pulmonary carcinoma]. Zhonghua Yi XueZaZhi. 87: 3272–3275